JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Tumor Markers in Differential Diagnosis of Benign Ovarian Masses

  • 0Department of Gynecology, Zhengzhou First People's Hospital, Zhengzhou, People's Republic of China.
International Journal of Women's Health +

|

September 23, 2024

|

September 23, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

This study shows that combining tumor markers like CA125 and HE4 can help diagnose common benign ovarian tumors, including luteal cysts and ovarian mature cystic teratoma (OMCT). These markers offer valuable insights for differential diagnosis in clinical practice.

Area Of Science

  • Gynecology
  • Oncology
  • Medical Diagnostics

Background

  • Benign ovarian adnexal masses are common, with luteal cysts, ovarian mature cystic teratomas (OMCT), ovarian endometriosis, and benign epithelial tumors being the most frequent.
  • Accurate differential diagnosis is crucial for appropriate patient management.

Purpose Of The Study

  • To evaluate the diagnostic value of six tumor markers (CEA, AFP, CA125, CA19-9, SCC, HE4) individually and in combination for differentiating common benign ovarian masses.
  • To assess the correlation between these markers and specific types of benign ovarian tumors.

Main Methods

  • A retrospective study of 135 female patients with adnexal benign masses treated between January 2018 and January 2023.
  • Patients were categorized into four groups: luteal cyst, OMCT, ovarian endometriosis, and benign epithelial tumors.
  • Receiver-operating characteristic (ROC) curve analysis was employed to determine the diagnostic accuracy (AUC, sensitivity, specificity) of each marker and their combinations.

Main Results

  • Combined markers showed significant diagnostic value: AFP, CA125, CA19-9, and SCC for luteal cysts (AUC=0.871); AFP, HE4, and SCC for OMCT (AUC=0.753); AFP, CA125, and CA19-9 for ovarian endometriosis (AUC=0.935); CA125 and CA19-9 for benign epithelial tumors (AUC=0.792).
  • Tumor size differed significantly among groups, with luteal cysts being smaller and epithelial tumors larger than others.
  • Specific markers showed higher levels in certain tumor types (e.g., CA125 in endometriosis, SCC in OMCT).

Conclusions

  • The combined use of CEA, AFP, CA125, CA19-9, SCC, and HE4 demonstrates significant potential in the differential diagnosis of common benign ovarian tumors.
  • While acknowledging limitations such as single-center data and sample size, these markers offer promising utility in clinical settings.
  • Further research with larger, multi-center cohorts is warranted to validate these findings.

Keywords: